<DOC>
	<DOCNO>NCT00661609</DOCNO>
	<brief_summary>The purpose Phase II study determine AZD4877 , experimental drug novel anti-mitotic agent ( Eg5 Kinesin Spindle Protein inhibitor interfere tumor cell division lead tumor growth ) , reduce tumor size patient bladder cancer</brief_summary>
	<brief_title>A Phase II Study AZD4877 ( Novel Anti-mitotic Agent ) Advanced Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Antimitotic Agents</mesh_term>
	<criteria>Confirmed urothelial cancer ( cancer bladder , renal pelvis , ureter , urethra ) . Tumor , Node , Metastasis ( TNM ) Stage IV urothelial cancer help curative surgery and/or curative radiotherapy Must maximum 2 prior chemotherapeutic regimen , one unremovable and/or metastasize disease , adjuvant neoadjuvant setting . Ambulatory capable selfcare 50 % waking hour Prior treatment investigational standard anticancer agent , include radiotherapy , within 4 week prior first dose study medication ; 6 week prior systemic mitomycin , nitrosourea , suramin . Inadequate bone marrow reserve Inadequate liver function presence liver metastasis Impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Anti-mitotic</keyword>
	<keyword>Eg5 Inhibitor</keyword>
	<keyword>Kinesin Spindle Protein Inhibitor</keyword>
	<keyword>Urothelial Cancer</keyword>
	<keyword>Bladder Cancer</keyword>
	<keyword>Renal Pelvis Cancer</keyword>
	<keyword>Urethra Cancer</keyword>
	<keyword>Ureter Cancer</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Advanced</keyword>
	<keyword>Stage IV</keyword>
</DOC>